Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Deletion of the short arm of chromosome 17 (del(17p)) is a well-established high-risk feature in multiple myeloma (MM) and is included in current disease staging criteria. Treatment of del(17p) MM is a major challenge, since the disease is characterized by rapid development of chemoresistance and short survival. The size of the del(17p) clone correlates with prognosis, and the threshold value of 55% to 60% has the worst prognosis. Approximately a third of patients (pts) have a concomitant TP53 mutation, with a complete abolition of the protein function. TP53 biallelic inactivation is defined as double-hit myeloma